Prostatype Genomics AB (PROGEN) AI Stock Analysis

• Market Cap: €35.45M
• Dividend Yield: N/A
• Average Volume (3M): 324.54K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.11
• Revenue Growth: -85.32%
• EPS Growth: 92.64%
• Country: SE
• Employees: 6
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.65
• Shares Outstanding: 37,000,263
• 10 Day Avg. Volume: 182,958
• 30 Day Avg. Volume: 324,535
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 35 Underperform
• Price Target: ―

Prostatype Genomics AB's overall stock score is low, primarily due to significant financial challenges, including ongoing losses and negative cash flows, which raise concerns about the company's sustainability. The technical analysis indicates a bearish trend, with all indicators pointing to weakness. The negative P/E ratio and absence of dividends further contribute to the low valuation score. To improve, the company needs to address its revenue generation and operational efficiencies.

Prostatype Genomics AB Business Overview & Revenue Model

Company Description

Prostatype Genomics AB (PROGEN) is a biotechnology company specializing in the development and commercialization of precision diagnostic tests for prostate cancer. The company's flagship product, Prostatype, is a gene expression test designed to assess the aggressiveness of prostate cancer, aiding clinicians in making more informed treatment decisions. Prostatype Genomics operates in the healthcare and life sciences sectors, focusing on improving patient outcomes through innovative genomic solutions.

How the Company Makes Money

Prostatype Genomics AB generates revenue primarily through the sale of its Prostatype test to healthcare providers and institutions. The company may partner with laboratories, hospitals, and clinics that administer the Prostatype test to patients, thus earning income from test sales and possible licensing agreements. Additionally, collaborations with research institutions and potential partnerships with pharmaceutical companies for joint research and development projects could provide supplementary revenue streams. The company's income is heavily reliant on the adoption and utilization of its testing solutions within the medical community, as well as its ability to expand into new markets and maintain regulatory approvals.

Prostatype Genomics AB Financial Statement Overview

Summary

Prostatype Genomics AB faces significant financial challenges with ongoing losses, inconsistent revenue growth, and reliance on external financing. While the balance sheet shows a strong equity position, the lack of profitability and negative cash flows indicate operational inefficiencies and potential sustainability risks.

Income Statement

Prostatype Genomics AB has consistently experienced negative net income and negative EBIT over the years, indicating ongoing operational losses. The gross profit margins are not sustainable as they are driven by minimal revenue and high costs. The revenue growth is highly inconsistent, with recent declines suggesting challenges in expanding its market presence.

Balance Sheet

The company maintains a healthy equity ratio, suggesting a strong equity position relative to total assets. However, the absence of total debt in recent reports reflects a lack of leverage, which could indicate limited access to external financing or a conservative financial strategy. The return on equity is negative due to ongoing losses, highlighting inefficiencies in generating returns from shareholders' equity.

Cash Flow

Prostatype Genomics AB's cash flow situation is concerning, with consistent negative free cash flow, indicating that the company is not generating enough cash from operations to fund its capital expenditures. The high operating cash outflow compared to net income suggests operational inefficiencies. The company relies heavily on financing cash flow to meet its cash needs, which could pose sustainability risks.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	199.00K	1.36M	683.00K	10.00K	683.88K
Gross Profit	1.92M	3.73M	683.00K	2.51M	-14.20M
EBITDA	-37.40M	-38.02M	-26.79M	-15.46M	-15.76M
Net Income	-41.05M	-41.44M	-29.09M	-15.63M	-17.41M
Balance Sheet
Total Assets	41.97M	49.22M	30.95M	40.20M	33.66M
Cash, Cash Equivalents and Short-Term Investments	9.42M	2.68M	11.49M	20.33M	15.86M
Total Debt	0.00	11.67M	867.00K	1.27M	1.47M
Total Liabilities	8.50M	24.55M	4.80M	4.30M	5.37M
Stockholders Equity	33.47M	24.67M	26.15M	35.91M	28.29M
Cash Flow
Free Cash Flow	-52.57M	-37.70M	-27.69M	-18.58M	-14.74M
Operating Cash Flow	-44.71M	-29.14M	-27.69M	-16.08M	-14.71M
Investing Cash Flow	-8.36M	-8.57M	0.00	-2.50M	-3.26M
Financing Cash Flow	59.75M	28.91M	18.85M	23.05M	31.14M

Prostatype Genomics AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.91
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PROGEN, the sentiment is Negative. The current price of 0.91 is below the 20-day moving average (MA) of 1.01, below the 50-day MA of 1.13, and below the 200-day MA of 3.09, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 40.05 is Neutral, neither overbought nor oversold. The STOCH value of 12.84 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PROGEN.

Prostatype Genomics AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMOTEC.B	54 Neutral	€62.80M	―	-236.60%	―	132.67%	58.89%
Sector *	51 Neutral	$7.38B	-0.04	-62.85%	2.34%	15.18%	-2.87%
PLUN	40 Underperform	kr1.78M	―	-44.57%	―	-30.56%	7.17%
PROGEN	35 Underperform	€35.45M	―	-181.36%	―	-85.32%	92.64%
STABL	34 Underperform	kr26.29M	―	-105.54%	―	―	63.82%
HEART	34 Underperform	kr67.98M	―		―	―	―
AINO	29 Underperform	kr45.01M	―		―	0.10%	41.59%